Waldenstrom’s Macroglobulinemia

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Note: Consider Clinical Trials as treatment options for eligible patients.

INITIAL WORK-UP

ESSENTIAL:
- History and physical exam
- CBC with differential, CMP, hepatitis B and C serology, cryocrit, cold agglutinin titer, LDH, beta-2 microglobulin, serum protein electrophoresis and immunofixation, serum free light chain assay (kappa and lambda), and quantitative immunoglobulins (IgG, IgM, IgA)
- 24 hour urine protein electrophoresis and immunofixation
- Unilateral bone marrow aspirate and biopsy
  - CXCR4 and MYD 88 L265 AS-PCR
  - PET/CT or CT neck, chest, abdomen and pelvis with IV contrast
- Lifestyle risk assessment

USEFUL IN CERTAIN PATIENTS:
- Fundoscopic examination
- Serum viscosity
- Coomb's Test
- Anti-myelin associated glycoprotein (MAG) antibody
- Anti-ganglioside monosialosyl l (GM1) antibody
- Electromyogram (EMG)
- Nerve conduction studies (NCS)
- Congo red staining of abdominal fat pad biopsy and/or bone marrow biopsy
- Prothrombin time (PT), Activated partial thromboplastin time (aPTT), Factor VIII (FVIII) coagulant activity, Ristocetin cofactor (RCOF) activity and concentration of vWF antigen (vWF:Ag)
- Brain/Spine MRI
- Lumbar puncture

Indications for treatment:
- Symptomatic hyperviscosity (eye grounds, neurologic changes)
- Anemia (Hgb < 10 grams/dL) or other cytopenias (due to marrow involvement/hypersplenism, cold agglutinin hemolytic anemia)
- Bulky adenopathy
- Symptomatic organomegaly
- Symptomatic cryoglobulinemia
- Amyloidosis
- Neuropathy
- Acquired von Willebrand disease
- CNS Involvement (Bing-Neel Syndrome)
- B symptoms

PRIMARY TREATMENT

- Clinical trial
- Bruton’s Tyrosine Kinase (BTK) inhibitor:
  - Zanubrutinib
  - Ibrutinib with or without rituximab
- Proteasome inhibitor based regimen:
  - Bortezomib/rituximab with or without dexamethasone
  - Carfilzomib/rituximab with dexamethasone
- Conventional chemotherapy based regimen:
  - Alkylation agent/rituximab
    - Bendamustine/rituximab
    - Rituximab/cyclophosphamide/dexamethasone
  - Nucleoside analog/rituximab
    - Cladribine/cyclophosphamide/rituximab
- Single-agent rituximab

See Page 2 for follow-up and surveillance

1 Cryocrit sample should be maintained at 37°C. If positive, maintain all Serum Protein Electrophoresis (SPEP) samples at 37°C until processed in the lab.
2 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice
3 When hyperviscosity is suspected
4 Most patients with serum viscosity of < 4 cP will not have symptoms of hyperviscosity
5 When hemolytic anemia is suspected
6 When symptoms or signs or peripheral neuropathy present
7 When amyloidosis suspected
8 If clinical bruising or bleeding present (concern for acquired von Willebrand disease)
9 When central nervous system involvement suspected
10 For rituximab intolerant patients, ofatumumab may be substituted in all rituximab containing regimens
11 Use alkylating agents and nucleoside analog-based regimen with caution in stem cell transplant candidates
12 The use of single-agent rituximab is discouraged, particularly in patients with M-protein > 5 grams/dL.
Waldenstrom’s Macroglobulinemia

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Note: Consider Clinical Trials as treatment options for eligible patients.

MANAGEMENT OF DISEASE RELAPSE

APPROACH TO CHOICE OF SALVAGE TREATMENT

RELAPSED/REFRACTORY TREATMENT OPTIONS

● Order the following prior to each cycle during systemic therapy and at least every 3-4 months during periods of observation:
  ○ CBC with differential
  ○ SPEP
  ○ Quantitative immunoglobulins (cryocrit and/or cold agglutinins if initially positive1)
  ○ Free kappa and free lambda light chains
  ○ 24-hour UPEP

● If abnormal finding were present during initial work-up scan, order the following every 3-6 months initially, then every 6-12 months:
  ○ PET/CT or CT neck, chest, abdomen and pelvis with IV contrast

1 Cryocrit sample should be maintained at 37°C. If positive, maintain all SPEP samples at 37°C until processed in the lab.

SPEP = Serum Protein Electrophoresis
UPEP = Urine Protein Electrophoresis

If ≥ partial response achieved (see Appendix B for response), observe until symptomatic or signs of end organ damage develop

If response to initial therapy with relapse < 12 months

Choose alternate therapy

If response to initial therapy with relapse ≥ 12 months

● May return to prior therapy or
● Choose alternate therapy

See Appendix A for supportive care measures

Clinical trial
BTK inhibitor:
  ○ Zanubrutinib
  ○ Ibrutinib with or without rituximab
  ○ Acalabrutinib

Proteasome inhibitor based regimen:
  ○ Bortezomib/rituximab with or without dexamethasone
  ○ Carfilzomib/rituximab with dexamethasone

Conventional chemotherapy based regimen:
  ○ Alkylating agent
    - Bendamustine/rituximab
    - Rituximab/cyclophosphamide/dexamethasone
  ○ Nucleoside analog2/rituximab
    - Cladribine/cyclophosphamide/rituximab
  ○ Autologous stem cell transplant (see Appendix C)
  ○ Allogeneic stem cell transplant (ablative or non-ablative)

Monoclonal antibody based regimen:
  ○ Rituximab3
  ○ Ofatumumab4

BCL-2 inhibitor:
  ○ Venetoclax

1 Cryocrit sample should be maintained at 37°C. If positive, maintain all SPEP samples at 37°C until processed in the lab.
2 Use alkylating agent and nucleoside analog-based regimens with caution in stem cell transplant candidates
3 For patients with M-protein > 5 grams/dL, use of rituximab alone is discouraged. Reports of transient increase in M-protein have been noted with the use of rituximab alone.
4 For rituximab intolerant patients, ofatumumab may be substituted in all rituximab containing regimens

Copyright 2021 The University of Texas MD Anderson Cancer Center

Department of Clinical Effectiveness V5
Approved by The Executive Committee of the Medical Staff on 11/16/2021
APPENDIX A: Supportive Care Measures

Infection:
- Intravenous immunoglobulin therapy should be considered in the setting of recurrent life-threatening infection, hypogammaglobulinemia, and/or if ≥ 3 infections/year
- Recommend COVID-19 vaccinations per CDC guidelines
- Recommend pneumococcal vaccinations (PCV13 and PPSV23) per CDC guidelines
- Recommend annual influenza vaccine
  - Recommend high-dose influenza vaccine for patients ≥ 65 years old and patients who have previously undergone a stem cell transplant (SCT)
- Herpes zoster prophylaxis is indicated for patients treated with proteasome inhibitors, daratumumab, and/or high dose dexamethasone
- Anti-Hepatitis B viral therapy is indicated in patients with active hepatitis B and those at risk of reactivation, who will be receiving rituximab or ofatumumab
- Consider avoiding concomitant quinolone therapy for patients on bortezomib-containing regimens
- Antifungal, antibacterial, and anti-zoster prophylaxis is indicated for patients receiving hyperfractionated cyclophosphamide-based therapy
- See Appendix D for post-transplant infection prophylaxis and vaccination schedule

Symptomatic Hyperviscosity:
- Plasmapheresis should be used as adjunctive therapy

GI Prophylaxis:
- Patients receiving steroids should receive prophylaxis with a proton pump inhibitor or H2-receptor antagonist

CDC = Centers for Disease Control and Prevention
PCV13 = pneumococcal conjugate vaccine
PPSV23 = pneumococcal polysaccharide vaccine
### APPENDIX B: Response Criteria for Waldenstrom’s macroglobulinemia

<table>
<thead>
<tr>
<th>Standard IWWM Criteria</th>
<th>Response Criteria</th>
</tr>
</thead>
</table>
| **Complete response**  | • IgM in normal range, **and** disappearance of monoclonal protein by immunofixation  
  • No histologic evidence of bone marrow involvement and resolution of any adenopathy/organomegaly, if present at baseline, along with no signs or symptoms attributable to Waldenstrom’s macroglobulinemia (WM)  
  • Reconfirmation of the complete response status is required by repeat immunofixation studies |
| **Very good partial response** | ≥ 90% reduction of serum IgM and decreases in adenopathy/organomegaly, if present at baseline, on physical examination or on CT\(^1\) scan **and** no new symptoms or signs of active disease |
| **Partial response** | ≥ 50% reduction of serum IgM and decrease in adenopathy/organomegaly, if present at baseline, on physical examination or on CT\(^1\) scan **and** no new symptoms or signs of active disease |
| **Minor response** | ≥ 25% but < 50% reduction of serum IgM and no new symptoms or signs of active disease |
| **Stable disease** | < 25% reduction **and** < 25% increase of serum IgM without progression of adenopathy/organomegaly, cytopenias, or clinically significant symptoms due to disease and/or signs of WM |
| **Progressive disease\(^2\)** | Any one or more of the following criteria:  
  • ≥ 25% increase in serum IgM by protein confirmed by a second measurement **or** progression of clinically significant findings due to disease (i.e., anemia, thrombocytopenia, leukopenia, bulky adenopathy/organomegaly)  
  • Symptoms (unexplained recurrent fever ≥ 38.4°C, drenching night sweats, ≥ 10% body weight loss, hyperviscosity, neuropathy, symptomatic cryoglobulinemia or amyloid) attributable to WM |

IWWM = International Workshop on Waldenstrom’s macroglobulinemia

\(^1\) CT scan may include chest, abdomen, and pelvis with contrast.

\(^2\) Requires two consecutive assessments made at any time before the institution of any new therapy.
# APPENDIX C: Considerations for Undergoing Autologous SCT

## Clinical Eligibility Criteria
- No uncontrolled cardio/pulmonary conditions
- Adequate peripheral venous access or adequate option for central venous access for autologous apheresis donors
- Negative pregnancy test for women of child-bearing potential
- No known allergy to cytokines if cytokines are to be used
- Patients with sickle cell anemia and other hemoglobinopathies are candidates for autologous stem cell transplant as long as their clinical condition permits the collection of sufficient stem cells
- Labs:
  - WBC - recommend > 3 K/microliter (minimum > 2 K/microliter)
  - Platelets - recommend > 75 K/microliter (minimum > 50 K/microliter)
  - No known allergy to cytokines if cytokines are to be used

## Clinical Suitability Criteria
- Adequate cardiac, renal, pulmonary, and hepatic function
# Waldenstrom’s Macroglobulinemia

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

## APPENDIX D: Post-SCT Infection Prophylaxis and Vaccination Schedule (Adults)

### Antibacterial Prophylaxis
- Levofloxacin 500 mg IV/PO once daily, starting Day -1 or if patient neutropenic at start of chemotherapy/admission (ANC ≤ 1 K/microliter)
  - Continue until ANC is > 1 K/microliter after engraftment or until patient becomes febrile
  - Adjust dose for CrCl < 50 mL/minute
- Alternative options (i.e., allergy or intolerance to fluoroquinolones)
  - Cefpodoxime 200 mg PO twice daily, starting Day -1 or if patient neutropenic at start of chemotherapy/admission (ANC ≤ 1 K/microliter)

### Antifungal Prophylaxis
- Fluconazole 400 mg PO IV daily from Day -1 until engraftment
-Alternative options (i.e., allergy or intolerance to azoles)
  - Caspofungin 50 mg IV once daily
- Prior history of mold infection:
  - Voriconazole 200 mg PO twice daily
  - Posaconazole 300 mg PO once daily

### PCP Prophylaxis

**Start by engraftment (Day +30 and ANC > 1.5 K/microliter) and continue for at least 6 months after transplant**

- **First line option:** sulfamethoxazole/trimethoprim (Bactrim)
  - Consider initiation of folic acid 1 mg PO once daily when patients started on Bactrim prophylaxis
  - Bactrim DS (800/160 mg) 1 tablet PO daily on Monday, Wednesday, and Friday or
  - Bactrim SS (400/80 mg) 1 tablet PO daily
  - Bactrim DS (800/160 mg) 1 tablet PO daily (reserve for patients with history of toxoplasmosis, history of toxoplasmosis IgG positive, or PCP)

### PCP Prophylaxis (continued)

- **Second line options (if sulfa intolerant):**
  - Consider sulfamethoxazole/trimethoprim desensitization in patients with mild rash or unknown reaction to sulfa
  - Inhaled pentamidine 300 mg every 21-28 days via Respigrad II nebulizer
  - Pentamidine 4 mg/kg IV over 90 minutes every 21 days
  - Atovaquone 1500 mg PO once daily
  - Dapsone 100 mg PO once daily
    - Test for G6PD deficiency prior to initiation of therapy
    - Avoid if history of life threatening reaction to sulfamethoxazole/trimethoprim

### Antiviral Prophylaxis
- **Hepatitis B Virus (HBV)**
  - Entecavir 0.5 mg PO daily
- **Herpes simplex virus (HSV)**
  - Valacyclovir 500 mg PO daily starting Day -1 and continue for 6-12 months after transplant
  - Alternative option: acyclovir 400 mg PO twice daily
  - If patient unable to take medications by mouth:
    - Acyclovir 250 mg/m² or 5 mg/kg IV every 12 hours
    - Patients with severe mucositis: acyclovir 250 mg/m² or 5 mg/kg IV every 8 hours
  - Adjust for renal impairment
- **Varicella zoster virus (VZV)**
  - Patients with a history of shingles or VZV seropositive
  - Valacyclovir 500 mg PO twice daily, starting Day -1 for 1 year
  - Alternative option: acyclovir 800 mg PO twice daily
  - If patient unable to take medications by mouth: acyclovir 250 mg/m² or 5 mg/kg IV every 8 hours

Continued on next page
### APPENDIX D: Post-SCT Infection Prophylaxis and Vaccination Schedule (Adults) - continued

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose/Route</th>
<th>Time Post Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&gt; 3 months</td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV, Prevnar 13®)</td>
<td>0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23, Pneumovax®)</td>
<td>0.5 mL SC or IM</td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae (Hib)</td>
<td>0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>Diphtheria, tetanus, acellular pertussis (DTaP)²</td>
<td>0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>Inactive polio (IPV)²</td>
<td>0.5 mL SC or IM</td>
<td>X</td>
</tr>
<tr>
<td>Hepatitis B (HepB)</td>
<td>≤ 19 years: 0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>≥ 20 years: 1 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>Hepatitis A (Havrix®)</td>
<td>≤ 18 years: 0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>≥ 19 years: 1 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>Seasonal influenza³ (Sept-March) (Fluzone High-Dose Quadrivalent®)</td>
<td>0.7 mL IM</td>
<td>X³</td>
</tr>
<tr>
<td>Recombinant varicella zoster vaccine (Shingrix®)³</td>
<td>0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>COVID-19⁶</td>
<td>3 Doses:</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Pfizer: 0.3 mL IM or</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Moderna: 0.5 mL IM</td>
<td>X</td>
</tr>
</tbody>
</table>

1 May substitute Tdap if DTaP unavailable
2 DTaP and IPV may be given via the combination Kinrix® at the same intervals per chart above
3 Continue yearly for life. In the setting of community outbreak, may start influenza vaccine as early as 3 months
4 Based on current studies, the recombinant varicella zoster vaccine (Shingrix®) appears to be a safe and efficacious option for post-autologous SCT patients 18 years and older. Continue herpes simplex virus (HSV)/VZV prophylaxis until vaccine series complete. This vaccine will not protect against HSV.
5 Second dose is 2 to 6 months after first dose

5 Wait until greater than 3 months from high dose chemotherapy/SCT. Pfizer-BioNTech vaccine is administered two doses 21 days apart with third dose administered ≥28 days after the second dose. Moderna vaccine is administered two doses 28 days apart with third dose administered ≥28 days after the second dose. CDC recommends third dose of the same mRNA vaccine to be used. Information may be subject to change, please refer to most updated CDC, FDA and ASH-ASTCT guidance.

Continued on next page
### APPENDIX D: Post-SCT Infection Prophylaxis and Vaccination Schedule (Adults) - continued

#### Optional Vaccines

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose/Route</th>
<th>Time Post Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>6 months</td>
</tr>
<tr>
<td>Measles, mumps, and rubella(^2) (MMR – live vaccine)</td>
<td>0.5 mL SC</td>
<td>Contraindicated(^3) in patients less than 24 months post-SCT, on immunosuppression (should be off immunosuppression for at least 12 months)</td>
</tr>
<tr>
<td>Human papilloma virus (HPV, Gardasil(^9))(^a)</td>
<td>0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>Meningococcal conjugate vaccine (MCV4, Menactra(^b))</td>
<td>0.5 mL IM</td>
<td>X</td>
</tr>
<tr>
<td>Meningococcal type B vaccine (Bexsero(^c))</td>
<td>0.5 mL IM</td>
<td>X</td>
</tr>
</tbody>
</table>

1. For live attenuated vaccines, patients must be ≥ 2 years post SCT, ≥ 1 year off immunosuppression, and ≥ 5 months since IVIG
2. For patients that are candidates for early vaccination need 2 doses. Minimum time interval between vaccines are 4 weeks
3. Additional contraindications to receive MMR
   - Pregnancy
   - CD4 count less than 200 for age 6 and older; CD4 count less than 500 for age 1 to 5 years
     - For autologous patients, if CD4 is not available, a normal lymphocyte count is adequate
   - On maintenance therapies to prevent relapse (i.e. tyrosine kinase inhibitors, etc)
   - Relapse leukemia or lymphoma and undergoing chemotherapy
     - Patients should be at least 3 months post-chemotherapy and in remission
   - Hypogammaglobulinemia, agammaglobulinemia or other severe immunodeficiency states
     - IgG should be within normal limits
4. Two doses 4 weeks apart
SUGGESTED READINGS

The following is not meant to be a comprehensive list of available effective treatments for Waldenstrom’s macroglobulinemia (WM); WM treatments are changing rapidly and new treatments and added information regarding previous treatments are available frequently. As a result, updates should be taken into consideration and for similar reasons, regimens reported only by abstract have been included on this reference list.

General Overview


Alkylating Agent Based Regimens


Nucleoside Analogue Based Regimens


Continued on next page
Bortezomib Based Regimens


Carfilzomib Based Regimens


Acalabrutinib Based Regimen


Ibrutinib Based Regimens


Continued on next page
Waldenström’s Macroglobulinemia

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued

Rituximab Based Regimens

Ofatumumab Based Regimens

BCL-2 Inhibitor

Continued on next page
SUGGESTED READINGS - continued

Stem Cell Transplant

Vaccinations
Waldenstrom’s Macroglobulinemia

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Myeloma Center Faculty at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Behrang Amini, MD, PhD (Musculoskeletal Imaging)
Melody R. Becnel, MD (Lymphoma/Myeloma)
Alison M. Gulbis, PharmD (Pharmacy Clinical Programs)
Olga N. Fleckenstein, BS
Alexandra Hacker, MSN, APRN, FNP-BC
Gregory P. Kaufman, MD (Lymphoma/Myeloma)
Hans C. Lee, MD (Lymphoma/Myeloma)
Elisabet Manasanch, MD (Lymphoma/Myeloma)
Robert Z. Orlowski, MD, PhD (Lymphoma/Myeloma)
Krina Patel, MD (Lymphoma/Myeloma)
Muzaffar H. Qazilbash, MD (Stem Cell Transplantation)
Sheeba K. Thomas, MD (Lymphoma/Myeloma)
Donna M. Weber, MD (Lymphoma/Myeloma)
Milena Zhang, PharmD

Core Development Team
Clinical Effectiveness Development Team